These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31350978)

  • 1. Evaluation of Protein Profiling in a Cohort of Egyptian Population with Renal Cell Carcinoma and Benign Kidney Neoplasms.
    Kandil NS; Ghazala RA; El Sharkawy RM; Youssif TA; Noha Abouseda N
    Asian Pac J Cancer Prev; 2019 Jul; 20(7):2145-2152. PubMed ID: 31350978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis reveals differentially secreted proteins in the urine from patients with clear cell renal cell carcinoma.
    Sandim V; Pereira Dde A; Kalume DE; Oliveira-Carvalho AL; Ornellas AA; Soares MR; Alves G; Zingali RB
    Urol Oncol; 2016 Jan; 34(1):5.e11-25. PubMed ID: 26420021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses].
    Xu G; Xiang CQ; Lu Y; Kang XN; Wang WJ; Liao P; Ding Q; Zhang YF
    Zhonghua Yi Xue Za Zhi; 2008 Mar; 88(12):858-60. PubMed ID: 18756995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SELDI-TOF-MS-based serum proteomic screening in combination with CT scan distinguishes renal cell carcinoma from benign renal tumors and healthy persons.
    Xu G; Xiang CQ; Lu Y; Wang WJ; Kang XN; Liao P; Ding Q; Zhang YF
    Technol Cancer Res Treat; 2009 Jun; 8(3):225-30. PubMed ID: 19445540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for the serum differential proteins of renal cell carcinoma using magnetic beads-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Liu JS; Li HZ; Zhang YS; Wang P; Yan WG; Xie J; Dong DX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Jun; 33(3):287-91. PubMed ID: 21718612
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the serum peptidome in renal cell carcinoma discriminating benign and malignant kidney tumors.
    Gianazza E; Chinello C; Mainini V; Cazzaniga M; Squeo V; Albo G; Signorini S; Di Pierro SS; Ferrero S; Nicolardi S; van der Burgt YE; Deelder AM; Magni F
    J Proteomics; 2012 Dec; 76 Spec No.():125-40. PubMed ID: 22868251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic identification of Reticulocalbin 1 as potential tumor marker in renal cell carcinoma.
    Giribaldi G; Barbero G; Mandili G; Daniele L; Khadjavi A; Notarpietro A; Ulliers D; Prato M; Minero VG; Battaglia A; Allasia M; Bosio A; Sapino A; Gontero P; Frea B; Fontana D; Destefanis P
    J Proteomics; 2013 Oct; 91():385-92. PubMed ID: 23916412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analyzing urinary proteome patterns of metabolic syndrome patients with early renal injury by magnet bead separation and matrix-assisted laser desorption ionization time-of-flight mass spectrometry].
    Gao BX; Li MX; Liu XJ; Cai JF; Fan XH; Yang XL; Li XM; Li XW
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):511-6. PubMed ID: 22338134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.
    Xu G; Xiang CQ; Lu Y; Kang XN; Liao P; Ding Q; Zhang YF
    Cancer Lett; 2009 Sep; 282(2):205-13. PubMed ID: 19362769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum and Urine Metabolic Fingerprints Characterize Renal Cell Carcinoma for Classification, Early Diagnosis, and Prognosis.
    Xu X; Fang Y; Wang Q; Zhai S; Liu W; Liu W; Wang R; Deng Q; Zhang J; Gu J; Huang Y; Liang D; Yang S; Chen Y; Zhang J; Xue W; Zheng J; Wang Y; Qian K; Zhai W
    Adv Sci (Weinh); 2024 Sep; 11(34):e2401919. PubMed ID: 38976567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining candidate mRNA and protein EV biomarkers to discriminate ccRCC and pRCC from non-malignant renal cells in vitro.
    Zieren RC; Dong L; Clark DJ; Kuczler MD; Horie K; Moreno LF; Lih TM; Schnaubelt M; Vermeulen L; Zhang H; de Reijke TM; Pienta KJ; Amend SR
    Med Oncol; 2021 Jul; 38(9):105. PubMed ID: 34331598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry.
    Hara T; Honda K; Ono M; Naito K; Hirohashi S; Yamada T
    J Urol; 2005 Oct; 174(4 Pt 1):1213-7. PubMed ID: 16145372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor size, stage and grade alterations of urinary peptidome in RCC.
    Chinello C; Cazzaniga M; De Sio G; Smith AJ; Grasso A; Rocco B; Signorini S; Grasso M; Bosari S; Zoppis I; Mauri G; Magni F
    J Transl Med; 2015 Oct; 13():332. PubMed ID: 26482227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary Application of WCX Magnetic Bead-Based Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry in Analyzing the Urine of Renal Clear Cell Carcinoma.
    Dong DX; Ji ZG; Li HZ; Yan WG; Zhang YS
    Chin Med Sci J; 2017 Dec; 32(4):248-252. PubMed ID: 29301600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Searching for prognostic biomarkers for small renal masses in the urinary proteome.
    Di Meo A; Batruch I; Brown MD; Yang C; Finelli A; Jewett MA; Diamandis EP; Yousef GM
    Int J Cancer; 2020 Apr; 146(8):2315-2325. PubMed ID: 31465112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma.
    Okamura N; Masuda T; Gotoh A; Shirakawa T; Terao S; Kaneko N; Suganuma K; Watanabe M; Matsubara T; Seto R; Matsumoto J; Kawakami M; Yamamori M; Nakamura T; Yagami T; Sakaeda T; Fujisawa M; Nishimura O; Okumura K
    Proteomics; 2008 Aug; 8(15):3194-203. PubMed ID: 18615424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential capture of serum proteins for expression profiling and biomarker discovery in pre- and posttreatment head and neck cancer samples.
    Freed GL; Cazares LH; Fichandler CE; Fuller TW; Sawyer CA; Stack BC; Schraff S; Semmes OJ; Wadsworth JT; Drake RR
    Laryngoscope; 2008 Jan; 118(1):61-8. PubMed ID: 18043497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons.
    Won Y; Song HJ; Kang TW; Kim JJ; Han BD; Lee SW
    Proteomics; 2003 Dec; 3(12):2310-6. PubMed ID: 14673781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteomic landscape of renal tumors.
    Chinello C; L'imperio V; Stella M; Smith AJ; Bovo G; Grasso A; Grasso M; Raimondo F; Pitto M; Pagni F; Magni F
    Expert Rev Proteomics; 2016 Dec; 13(12):1103-1120. PubMed ID: 27748142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.